/stocks — the workspaceLOADING
All FTH SEC filings, by type → · Earnings date & implied move · Search inside filings
FTH is not among the 142 companies we ingest every day, so it is not in the fundamentals screener or the size and group lists built from it. This page reads its SEC filings when the page is built. Ask us to add it: we keep a count per ticker and nothing about you.
Latest report (10-Q, filed 2026-11-03). Three months to 2026-09-30 against 2025-09-30: Net loss $20.4M, 346.4% larger than $4.6M. Nine months to 2026-09-30 against 2025-09-30: Operating cash used $39.4M, 137.6% larger than $16.6M. Read it line by line, each linked to its source → · Every report →
Faeth Therapeutics, Inc. (FTH) is a pharmaceutical preparations company. 3 insider Form 4 filings in the last 90 days. Next earnings projected around 2027-03-29 from FTH's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
Every filed figure on this page is free to read, dated and sourced; no column is held back for a paid plan. Each section with figures says what date they are true as of and where they come from.
What’s behind FTH’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has FTH been issuing shares? Offering history →
Volume against its own history: 100% of its last 100 sessions were lighter than the last one, the 2026-11-09 session. End-of-day bars (Databento). Volume detail
| Free cash flow per share | That year | Year before, same report | Change | Report |
|---|---|---|---|---|
| fiscal 2025 | -16.24 USD | -19.76 USD | not a growth rate (a year at or below zero) | 10-K filed 2026-03-30 |
| fiscal 2024 | -0.99 USD | -1.15 USD | not a growth rate (a year at or below zero) | 10-K filed 2025-03-28 |
| fiscal 2023 | -1.15 USD | -1.28 USD | not a growth rate (a year at or below zero) | 10-K filed 2024-02-29 |
| fiscal 2022 | -1.28 USD | -1.17 USD | not a growth rate (a year at or below zero) | 10-K filed 2023-03-29 |
| fiscal 2021 | -1.17 USD | -11.79 USD | not a growth rate (a year at or below zero) | 10-K filed 2022-03-15 |
Concepts read: (us-gaap:NetCashProvidedByUsedInOperatingActivities - us-gaap:PaymentsToAcquirePropertyPlantAndEquipment) / us-gaap:NetIncomeLoss / us-gaap:EarningsPerShareBasicAndDiluted; (us-gaap:NetCashProvidedByUsedInOperatingActivities - us-gaap:PaymentsToAcquirePropertyPlantAndEquipment) / us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
| Diluted EPS | That year | Year before, same report | Change | Report |
|---|---|---|---|---|
| fiscal 2025 | -16.72 USD | -24.01 USD | not a growth rate (a year at or below zero) | 10-K filed 2026-03-30 |
| fiscal 2024 | -1.20 USD | -1.22 USD | not a growth rate (a year at or below zero) | 10-K filed 2025-03-28 |
| fiscal 2023 | -1.22 USD | -1.58 USD | not a growth rate (a year at or below zero) | 10-K filed 2024-02-29 |
| fiscal 2022 | -1.58 USD | -1.33 USD | not a growth rate (a year at or below zero) | 10-K filed 2023-03-29 |
| fiscal 2021 | -1.33 USD | -12.53 USD | not a growth rate (a year at or below zero) | 10-K filed 2022-03-15 |
Concepts read: us-gaap:EarningsPerShareBasicAndDiluted; us-gaap:EarningsPerShareDiluted
Per filed share, as each report states it. Free cash flow per share is operating cash flow less capital expenditure, over the diluted weighted average share count (or net income over diluted EPS where the count is tagged per share class).
Each year’s change comes from one annual report, which states that year and the year before on the same share basis, and the rate compounds those changes; so a split or a restatement between reports cannot bend it. A rate needs a positive figure at both ends of its window. The DCF above grows total free cash flow and divides by today’s share count, so a per-share rate also carries the buybacks or new shares of those years. These are past figures, not a forecast.
Not shown yet: the P/E range FTH has traded at, which would set the discount rate and terminal assumptions against its own history. It needs a long daily price history we are not yet licensed to display.
No sensitivity grid: free cash flow is not positive, so the DCF gives no value at any growth or discount rate.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from FTH’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
Not reported in XBRL for this filer.
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as FTH tagged it: net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
A plain-English read on FTH plus an auto-SWOT, built from FTH's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts, a bull, a bear, a risk manager, and a PM, debate FTH using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Ask about FTH’s revenue, earnings, valuation, filings, insiders or Congress trades. Answers come only from the numbered evidence the research brief uses, each citing the items it rests on. A question about one figure is answered by code, free. One that puts figures together is 1 generation (Pro). A question about whether to buy, sell or hold, how much, or where the price goes gets a refusal.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Closes only, split-adjusted. Range of the 101 sessions on file, under a full year. An average needs that many sessions on file to print. These are measurements, not support, resistance or targets. Chart with studies
Withheld: 200-session average (needs 200 sessions; 101 are on file).
Daily closes from 2026-06-17 through 2026-11-09, 101 sessions, split-adjusted. No direction, pattern, entry, target or overbought label: these are measurements. Filings dated on the move days are in FTH’s filings; the chart with studies draws every figure.
Written by code from 101 end-of-day bars through 2026-11-09. Written by code from the data on file, not by a model. Information, not investment advice: it describes the security and recommends nothing to anyone.
Projected from FTH's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentFTH files or announces.
| Reported | Close-to-close |
|---|---|
| 2026-11-03 | +4.0% |
| 2026-08-04 | -10.1% |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
Nothing on file for FTH from Nov 10, 2026 to Nov 23, 2026 in these sources: earnings date and filing deadline.
| Event | Result |
|---|---|
| Earnings date | nothing in the window. Nothing in the window. The next report is projected around Mar 29, 2027, after it. |
| Filing deadline | nothing in the window. Nothing in the window: the 10-K for the fiscal year ending Dec 31, 2026, due 60 to 90 days after it as SEC states no filer status for it, the span covers every status, falls due between Mar 1, 2027 and Mar 31, 2027, after it. Newest periodic report on file: the 10-Q for the period ending Sep 30, 2026, filed Nov 3, 2026. filing list on EDGAR |
| Ex-dividend date | not covered. Not checked. This attestation does not cover ex-dividend dates. |
This records what these sources returned when they were read. It is not a forecast: a company can announce an event at any time, and ex-dividend dates are not covered. Window 2026-11-10 to 2026-11-23, Eastern dates. Deadlines follow SEC Rules 13a-1 and 13a-13 and Form 20-F, moved past weekends and federal holidays by Rule 0-3.
1 of the 1 checks that ran found nothing new for FTH. 3 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
1 of 5 estimators could run on FTH's filings. A band needs at least 2.
One estimator is a point estimate, not a range, so no band and no valuation label are published for FTH. Below is everything that was checked, so the refusal can be read rather than taken on trust.
No sector peer set is priced for FTH, so sector medians could not fill the gaps.
Every refusal recorded for FTH → · How often we decline, and why →
The fair-value line is FTH’s own median P/E, P/S, P/B and P/FCF applied to each year’s fundamentals — the price its typical valuation would have implied. Where the solid line sits above the dashed one, the stock traded at a premium to its own history that year; below, a discount. This is a description of past valuation, computed from FTH’s filings and price history — not a forecast and not investment advice. A stock can trade above or below its own median for years.
Total return including reinvested dividends, from FTH’s adjusted closing prices. Past return is not a forecast and not investment advice.
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.
Group: Pharmaceutical Preparations, the SEC industry code FTH files under. 10 companies in our stored table file under it.
| Metric | FTH | Group median | 25th to 75th percentile | Where FTH sits |
|---|---|---|---|---|
| Net marginnet income divided by revenue, same fiscal year | not placed | 21.4%⊙INFERENCE — derived by arithmetic SourceNet margin across the 10 companies filing under SEC SIC "Pharmaceutical Preparations" in our stored table As offiscal years ended 2025-12-28 to 2025-12-31 HowEach company's net income divided by revenue, same fiscal year, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. A group prints from 6 companies with the figure. | 13.0% to 28.4% | FTH has no annual report in the stored table yet, so it has no figure to place. |
| Free cash flow marginoperating cash flow less capital expenditure, divided by revenue, same fiscal year | not placed | 20.9%⊙INFERENCE — derived by arithmetic SourceFree cash flow margin across the 9 companies filing under SEC SIC "Pharmaceutical Preparations" in our stored table As offiscal years ended 2025-12-28 to 2025-12-31 HowEach company's operating cash flow less capital expenditure, divided by revenue, same fiscal year, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. 1 of the 10 companies in the group lack the figure and are not counted. A group prints from 6 companies with the figure. | 16.7% to 26.7% | FTH has no annual report in the stored table yet, so it has no figure to place. |
| Return on equitynet income divided by stockholders’ equity at the fiscal year end | not placed | 32.9%⊙INFERENCE — derived by arithmetic SourceReturn on equity across the 9 companies filing under SEC SIC "Pharmaceutical Preparations" in our stored table As offiscal years ended 2025-12-28 to 2025-12-31 HowEach company's net income divided by stockholders’ equity at the fiscal year end, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. 1 of the 10 companies in the group lack the figure and are not counted. A group prints from 6 companies with the figure. | 12.5% to 38.2% | FTH has no annual report in the stored table yet, so it has no figure to place. |
One filed metric per row, each a ratio of two figures from the same annual report; no composite and no grade. Percentile is the share of the group’s other companies with a lower figure. A group prints from 6 companies with the figure. The group is drawn from our stored table (the S&P 500 issuers and the companies we cover, each with its newest annual report read), not from every filer in the class. Industry pages show the same medians by group.
Head office: Austin, Texas, United States · the company’s charter and its head office are in different states.
Source: the cover page of Faeth Therapeutics, Inc.’s 10-Q filed 2026-11-03, on EDGAR. Filings checked 2026-11-10. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
No tracked institution reported a position in FTH in the latest 13F round.
Of 5 sales in the last ~6 months, 0 were filed with the Rule 10b5-1 box checked, set up in advance under a written trading plan; 5 were filed without it.
| STEPHENSON BRIAN CChief Financial Officer | BUY | $326K | view → |
| STEPHENSON BRIAN CChief Financial Officer | BUY | $401K | view → |
| Parikh Anand KiranPresident and CEO | BUY | $55K | view → |
| STEPHENSON BRIAN CChief Financial Officer | BUY | $406K | view → |
| Cambrian BioPharma Inc10% owner | SELL | $501K | view → |
| Peyer James10% owner | SELL | $501K | view → |
| MILLENNIUM MANAGEMENT LLC10% owner | SELL | $538K | view → |
| MILLENNIUM MANAGEMENT LLC10% owner | BUY | $141K | view → |
No lawmaker has disclosed a trade in FTH under the STOCK Act.